Abstract: The invention provides combination therapy, wherein one or more other therapeutic agents are administered agents are administered with peptide epoxyketones or a pharmaceutically acceptable salt thereof. Another aspect of the invention relates to treating cancer with a peptide epoxyketone administered in combination with another therapeutic agent.
Type:
Grant
Filed:
November 2, 2016
Date of Patent:
March 24, 2020
Assignee:
ONYX THERAPEUTICS, INC.
Inventors:
Christopher J. Kirk, Susan D. Demo, Mark K. Bennett
Abstract: The present application relates to the use of pertussis toxin, and its derivatives, analogs, salts and pharmaceutical equivalents. In one embodiment, the invention provides a method of treating or preventing a neurological disease or injury by administering pertussis toxin to the individual.
Abstract: A resonator sensor module is disclosed. The resonator sensor module includes one or more sensing resonators that includes binding sites for an analyte material; one or more reference resonators that lacks any binding sites for the analyte material; a module interface; and one or more switches each including a first position that operatively couples at least one of the one or more sensing resonators and the module interface and a second position that operatively couples at least one of the one or more reference resonators and the module interface.
Abstract: An antigen detection method using sandwich immunoassay includes a first reaction step of preparing a sensor chip, which includes a fine flow channel in which a reaction zone having an antigen-capturing antibody immobilized thereon is arranged, a liquid discharge/suction section and a liquid-mixing section, and subsequently feeding thereto a sample liquid so as to allow the antigen-capturing antibody to capture a target; and a second reaction step of allowing a labeling liquid containing a labeling antibody to flow into the fine flow channel so as to label the target. In the antigen detection method, the labeling liquid does not reach the liquid-mixing section. According to the antigen detection method, the accuracy and the repeatability of the target measurement can be improved.
Abstract: The invention relates to carrier complexes and methods for delivering molecules to cells. The carrier complexes comprises a molecule and an aromatic cationic peptide in accordance with the invention. In one embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a carrier complex. In another embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a molecule and an aromatic cationic peptide.
Type:
Grant
Filed:
March 11, 2016
Date of Patent:
March 10, 2020
Assignee:
Cornell Research Foundation, Inc.
Inventors:
Hazel H. Szeto, Kesheng Zhao, Hugh Robertson, Alex V. Birk
Abstract: Embodiments of the present disclosure provide for systems of enhancing the signal to noise ratio, methods of orienting a nanomaterial (e.g., an antibody), methods of enhancing the signal to noise ratio in a system (e.g., an assay system), and the like.
Type:
Grant
Filed:
October 24, 2014
Date of Patent:
March 10, 2020
Assignee:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Inventors:
Sam Emaminejad, Mehdi Javanmard, Chaitanya Gupta, Roger T. Howe
Abstract: There are provided methods, and devices for assaying for a binding interaction between a protein, such as a monoclonal antibody, produced by a cell, and a biomolecule. The method may include retaining the cell within a chamber having an aperture; exposing the protein produced by the cell to a capture substrate, wherein the capture substrate is in fluid communication with the protein produced by the cell and wherein the capture substrate is operable to bind the protein produced by the cell; flowing a fluid volume comprising the biomolecule through the chamber via said aperture, wherein the fluid volume is in fluid communication with the capture substrate; and determining a binding interaction between the protein produced by the cell and the biomolecule.
Type:
Grant
Filed:
September 23, 2019
Date of Patent:
March 3, 2020
Assignee:
The University of British Columbia
Inventors:
Anupam Singhal, Carl L. G. Hansen, John W. Schrader, Charles A. Haynes, Daniel J. Da Costa
Abstract: Disclosed are a kit for testing myocardial infarction rapidly and a preparation method and use thereof. The kit comprises a strip capable of detecting three markers, namely, human myeloperoxidase (MPO), heart-fatty acid binding protein (FABP3) and cardiac troponin I (cTnI) simultaneously. The strip comprises a sample pad, a conjugate pad, a chromatographic membrane coated with three test lines and a quality control line, and a sample absorption pad. Antibodies of the three markers are all marked on the conjugate pad. The chromatographic membrane has three test lines formed by coating paired antibodies of the three markers respectively, the paired antibodies of the three markers being able to specifically combine with the three markers, respectively. The kit has advantages such as convenient operation, rapid response, high sensitivity and high specificity, point of care test, and economical and practical etc.
Abstract: Disclosed is a method for preparing ganirelix acetate. The method includes the following steps: respectively replacing Fmoc-HArg(Et)2-OH and Fmoc-D-HArg(Et)2-OH by employing Fmoc-Lys(Boc)-OH and Fmoc-D-Lys(Boc)-OH or Fmoc-Lys(Alloc)-OH and Fmoc-D-Lys(Alloc)-OH; synthesizing a ganirelix precursor I or ganirelix precursor II-peptide resin in advance; and then respectively performing modifications and treatments on side chain amino groups of Lys and D-Lys in the precursor I or the precursor II-peptide resin to obtain ganirelix acetate. The ganirelix acetate synthesized therefrom is high in purity, has few impurities and a relatively low cost, and is suitable for large-scale production.
Abstract: Disclosed herein are devices and methods that use aqueous two phase systems and lateral flow assays to detect target analytes in a sample. These devices and methods may be used to diagnose a disease or condition in a biological sample, such as blood or serum. In addition, these devices and methods may be used to detect allergens in a food samples or contaminants, such as environmental toxins, in water samples. Device and kit components may be conveniently assembled in a portable container and are amenable to actuation in most settings. The devices are simple to use, requiring a non-trained operator to simply add the sample to the device. Conveniently, the time it takes to detect the target analyte is very short. Thus, the devices and methods disclosed herein provide novel and useful means for point-of-care.
Type:
Grant
Filed:
June 6, 2019
Date of Patent:
March 3, 2020
Assignee:
The Regents of the University of California
Inventors:
Daniel Takashi Kamei, Yin To Chiu, Benjamin Ming Wu, Garrett L. Mosley
Abstract: The present invention relates to antimicrobial peptides of the general formula AxByCz with x, z?1, y?3 and x+y+z?50, where A and C, in each case independently of one another, have at least 65% basic amino acids and B has at least 65% hydrophobic and/or nonpolar amino acids and comprises a direct sequence of at least three hydrophobic amino acids. Moreover, a medical use of the peptides, a conjugate and an antimicrobial composition are indicated.
Type:
Grant
Filed:
February 9, 2015
Date of Patent:
February 11, 2020
Assignee:
Fraunhofer-Gesellschaft
Inventors:
Karsten Rapsch, Markus v. Nickisch-Rosenegk
Abstract: Disclosed are embodiments of a lateral flow test strip (LFTS) platform which measure osteocalcin (OC) and deoxypyridinoline (Dpd) in saliva to identify early indications of bone loss and minimize bone fracture risk associated with osteoporosis. The OC assay embodiments are based on the experimentally identified optimal markers which exhibit selectivity with very low false positives, and sensitivity relevant to clinical requirements. A prospective clinical study sampling of 20 patients demonstrated excellent correlation of OC in saliva with bone mineral density (BMD). Salivary OC and Dpd levels were validated with a standard commercial ELISA kit against serum (OC) and urine (Dpd).